Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates

WD Stein, C Cardarelli, I Pastan and MM Gottesman

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

A kinetic approach was used to analyze the mechanism by which a substitution of valine for glycine at position 185 in the multidrug transporter alters its substrate specificity so that colchicine and etoposide transport is increased, daunorubicin transport is unchanged, and vinblastine transport is decreased. Time courses for uptake and efflux of colchicine, vinblastine, etoposide, and daunorubicin for NIH/3T3 mouse cells transfected with wild-type (MDR1-G185) and mutant (MDR1-V185) strains of the human mdr1 gene were determined at room temperature in the presence and absence of an energy supply. The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants. In contrast, glucose feeding decreased the initial rate of colchicine uptake approximately 4-fold in the MDR1-V185 (mutant) transfectant but not in the MDR1-G185 (wild- type) transfectant. Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels. The effects on initial rates of colchicine uptake accounted semiquantitatively for the increased colchicine resistance of MDR1-V185 (mutant) transfectants. Similar effects were found for etoposide in the MDR-V185 transfectants. Quinidine in the external medium greatly inhibited drug entry rates but had little effect on efflux, whereas verapamil inhibited both uptake and efflux. A possible interpretation of these data is that the multidrug transporter extracts drugs from the external and internal halves of the membrane bilayer by different paths, which are distinguishable by mutation and inhibitors.

Volume 45, Issue 4, pp. 763-772, 04/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. F. K. Ejendal and C. A. Hrycyna Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911. [Abstract] [Full Text] [PDF]

				S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467. [Abstract] [Full Text] [PDF]

				S. U. C. Sankatsing, J. H. Beijnen, A. H. Schinkel, J. M. A. Lange, and J. M. Prins P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1073 - 1081. [Full Text] [PDF]

				N. Maki, P. Hafkemeyer, and S. Dey Allosteric Modulation of Human P-glycoprotein. INHIBITION OF TRANSPORT BY PREVENTING SUBSTRATE TRANSLOCATION AND DISSOCIATION J. Biol. Chem., May 9, 2003; 278(20): 18132 - 18139. [Abstract] [Full Text] [PDF]

				J. R. Murren Modulating Multidrug Resistance: Can We Target this Therapy? Clin. Cancer Res., March 1, 2002; 8(3): 633 - 635. [Full Text] [PDF]

				J. M. Baron, L. B. Goh, D. Yao, C. R. Wolf, and T. Friedberg Modulation of P450 CYP3A4-Dependent Metabolism by P-glycoprotein: Implications for P450 Phenotyping J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 351 - 358. [Abstract] [Full Text]

				D. E. Lorke, M. Krüger, R. Buchert, K. H. Bohuslavizki, M. Clausen, and U. Schumacher In Vitro and In Vivo Tracer Characteristics of an Established Multidrug-Resistant Human Colon Cancer Cell Line J. Nucl. Med., April 1, 2001; 42(4): 646 - 654. [Abstract] [Full Text]

				C. G. L. LEE, M. RAMACHANDRA, K.-T. JEANG, M. A. MARTIN, I. PASTAN, and M. M. GOTTESMAN Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter FASEB J, March 1, 2000; 14(3): 516 - 522. [Abstract] [Full Text]

				T. Shoshani, S. Zhang, S. Dey, I. Pastan, and M. M. Gottesman Analysis of Random Recombination between Human MDR1 and Mouse Mdr1a cDNA in a pHaMDR-Dihydrofolate Reductase Bicistronic Expression System Mol. Pharmacol., October 1, 1998; 54(4): 623 - 630. [Abstract] [Full Text]

				S. Dey, M. Ramachandra, I. Pastan, M. M. Gottesman, and S. V. Ambudkar Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein PNAS, September 30, 1997; 94(20): 10594 - 10599. [Abstract] [Full Text] [PDF]

				A. Ocaktan, H. Yoneyama, and T. Nakae Use of Fluorescence Probes to Monitor Function of the Subunit Proteins of the MexA-MexB-OprM Drug Extrusion Machinery in Pseudomonas aeruginosa J. Biol. Chem., August 29, 1997; 272(35): 21964 - 21969. [Abstract] [Full Text] [PDF]

				S. V. Ambudkar, C. O. Cardarelli, I. Pashinsky, and W. D. Stein Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein J. Biol. Chem., August 22, 1997; 272(34): 21160 - 21166. [Abstract] [Full Text] [PDF]

				H. Bolhuis, H. W. van Veen, J. R. Brands, M. Putman, B. Poolman, A. J.M. Driessen, and W. N. Konings Energetics and Mechanism of Drug Transport Mediated by the Lactococcal Multidrug Transporter LmrP J. Biol. Chem., September 27, 1996; 271(39): 24123 - 24128. [Abstract] [Full Text] [PDF]

				A. B. Shapiro and V. Ling Reconstitution of Drug Transport by Purified P-glycoprotein J. Biol. Chem., June 7, 1995; 270(27): 16167 - 16175. [Abstract] [Full Text] [PDF]

				M.M. Gottesman, S.V. Ambudkar, B. Ni, J.M. Aran, Y. Sugimoto, C.O. Cardarelli, and I. Pastan Exploiting Multidrug Resistance to Treat Cancer Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 677 - 683. [Abstract] [PDF]